Eyebrows Raised As Roche Inks Cardiovascular Pact With Alnylam

Bags Rights To Hypertension Therapy Zilebesiran

24 Jul 2023

The Swiss major is so keen to get access to Alnylam’s RNAi therapeutic targeting angiotensinogen that it is paying $310m upfront having only seen Phase I data. Some analysts are unsure if it is a good idea.

Roche Holding AG has taken the surprising step of jumping into the cardiovascular space and teamed up with Alnylam Pharmaceuticals Inc. to co-develop and co-commercialize zilebesiran, the RNA interference (RNAi) specialist's keenly-watched twice-yearly injection for hypertension.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

18 Apr 2025

• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

15 Apr 2025

• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

15 Apr 2025

• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

14 Apr 2025

• By Alaric DeArment

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

21 Apr 2025

• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.